Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: A pilot study

Taku Fujimura, Yota Sato, Kayo Tanita, Yumi Kambayashi, Atsushi Otsuka, Yasuhiro Fujisawa, Koji Yoshino, Shigeto Matsushita, Takeru Funakoshi, Hiroo Hata, Yuki Yamamoto, Hiroshi Uchi, Yumi Nonomura, Ryota Tanaka, Megumi Aoki, Keisuke Imafuku, Hisako Okuhira, Sadanori Furudate, Takanori Hidaka, Setsuya Aiba

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Antibodies against PD-1, such as nivolumab and pembrolizumab, are widely used in the treatment of various cancers including advanced melanoma. The anti- PD-1 Ab significantly prolongs survival in patients with metastatic melanoma, and its administration in combination with local or systemic therapy may also lead to improved outcomes. Although anti-PD-1 Ab-based combined therapy might be effective for the treatment of advanced melanoma, the associated risk of irAEs is an important consideration. Therefore, being able to predict irAEs is of great interest to oncologists. The purpose of this study was to evaluate the value of using serum levels of sCD163 and CXCL5 to predict irAEs in patients with advanced melanoma who were administered nivolumab. To this end, we analyzed these serum levels in 46 cases of advanced melanoma treated with nivolumab. In addition, the tumor stroma was evaluated by immunohistochemistry and immunofluorescence. We measured the serum levels of sCD163 and CXCL5 on day 0 (immediately before nivolumab administration) and day 42. The serum absolute levels of sCD163 were significantly increased in patients who developed AEs (p = 0.0018). Although there was no significant difference in serum levels of CXCL5, the absolute value of CXCL5 could at least be a supportive marker for the increased absolute levels of serum sCD163. This study suggests that sCD163 and CXCL5 may serve as possible prognostic biomarkers for irAEs in patients with advanced melanoma treated with nivolumab.

Original languageEnglish
Pages (from-to)15542-15551
Number of pages10
JournalOncotarget
Volume9
Issue number21
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Melanoma
Biomarkers
Serum
Therapeutics
Fluorescent Antibody Technique
nivolumab
Neoplasms
Immunohistochemistry
Survival
Antibodies

Keywords

  • CXCL5
  • Melanoma
  • POSTN
  • SCD163
  • TAMs

ASJC Scopus subject areas

  • Oncology

Cite this

Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab : A pilot study. / Fujimura, Taku; Sato, Yota; Tanita, Kayo; Kambayashi, Yumi; Otsuka, Atsushi; Fujisawa, Yasuhiro; Yoshino, Koji; Matsushita, Shigeto; Funakoshi, Takeru; Hata, Hiroo; Yamamoto, Yuki; Uchi, Hiroshi; Nonomura, Yumi; Tanaka, Ryota; Aoki, Megumi; Imafuku, Keisuke; Okuhira, Hisako; Furudate, Sadanori; Hidaka, Takanori; Aiba, Setsuya.

In: Oncotarget, Vol. 9, No. 21, 01.01.2018, p. 15542-15551.

Research output: Contribution to journalArticle

Fujimura, T, Sato, Y, Tanita, K, Kambayashi, Y, Otsuka, A, Fujisawa, Y, Yoshino, K, Matsushita, S, Funakoshi, T, Hata, H, Yamamoto, Y, Uchi, H, Nonomura, Y, Tanaka, R, Aoki, M, Imafuku, K, Okuhira, H, Furudate, S, Hidaka, T & Aiba, S 2018, 'Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: A pilot study', Oncotarget, vol. 9, no. 21, pp. 15542-15551. https://doi.org/10.18632/oncotarget.24509
Fujimura, Taku ; Sato, Yota ; Tanita, Kayo ; Kambayashi, Yumi ; Otsuka, Atsushi ; Fujisawa, Yasuhiro ; Yoshino, Koji ; Matsushita, Shigeto ; Funakoshi, Takeru ; Hata, Hiroo ; Yamamoto, Yuki ; Uchi, Hiroshi ; Nonomura, Yumi ; Tanaka, Ryota ; Aoki, Megumi ; Imafuku, Keisuke ; Okuhira, Hisako ; Furudate, Sadanori ; Hidaka, Takanori ; Aiba, Setsuya. / Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab : A pilot study. In: Oncotarget. 2018 ; Vol. 9, No. 21. pp. 15542-15551.
@article{c79ff348636446478e5d4811d16124cf,
title = "Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: A pilot study",
abstract = "Antibodies against PD-1, such as nivolumab and pembrolizumab, are widely used in the treatment of various cancers including advanced melanoma. The anti- PD-1 Ab significantly prolongs survival in patients with metastatic melanoma, and its administration in combination with local or systemic therapy may also lead to improved outcomes. Although anti-PD-1 Ab-based combined therapy might be effective for the treatment of advanced melanoma, the associated risk of irAEs is an important consideration. Therefore, being able to predict irAEs is of great interest to oncologists. The purpose of this study was to evaluate the value of using serum levels of sCD163 and CXCL5 to predict irAEs in patients with advanced melanoma who were administered nivolumab. To this end, we analyzed these serum levels in 46 cases of advanced melanoma treated with nivolumab. In addition, the tumor stroma was evaluated by immunohistochemistry and immunofluorescence. We measured the serum levels of sCD163 and CXCL5 on day 0 (immediately before nivolumab administration) and day 42. The serum absolute levels of sCD163 were significantly increased in patients who developed AEs (p = 0.0018). Although there was no significant difference in serum levels of CXCL5, the absolute value of CXCL5 could at least be a supportive marker for the increased absolute levels of serum sCD163. This study suggests that sCD163 and CXCL5 may serve as possible prognostic biomarkers for irAEs in patients with advanced melanoma treated with nivolumab.",
keywords = "CXCL5, Melanoma, POSTN, SCD163, TAMs",
author = "Taku Fujimura and Yota Sato and Kayo Tanita and Yumi Kambayashi and Atsushi Otsuka and Yasuhiro Fujisawa and Koji Yoshino and Shigeto Matsushita and Takeru Funakoshi and Hiroo Hata and Yuki Yamamoto and Hiroshi Uchi and Yumi Nonomura and Ryota Tanaka and Megumi Aoki and Keisuke Imafuku and Hisako Okuhira and Sadanori Furudate and Takanori Hidaka and Setsuya Aiba",
year = "2018",
month = "1",
day = "1",
doi = "10.18632/oncotarget.24509",
language = "English",
volume = "9",
pages = "15542--15551",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "21",

}

TY - JOUR

T1 - Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab

T2 - A pilot study

AU - Fujimura, Taku

AU - Sato, Yota

AU - Tanita, Kayo

AU - Kambayashi, Yumi

AU - Otsuka, Atsushi

AU - Fujisawa, Yasuhiro

AU - Yoshino, Koji

AU - Matsushita, Shigeto

AU - Funakoshi, Takeru

AU - Hata, Hiroo

AU - Yamamoto, Yuki

AU - Uchi, Hiroshi

AU - Nonomura, Yumi

AU - Tanaka, Ryota

AU - Aoki, Megumi

AU - Imafuku, Keisuke

AU - Okuhira, Hisako

AU - Furudate, Sadanori

AU - Hidaka, Takanori

AU - Aiba, Setsuya

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Antibodies against PD-1, such as nivolumab and pembrolizumab, are widely used in the treatment of various cancers including advanced melanoma. The anti- PD-1 Ab significantly prolongs survival in patients with metastatic melanoma, and its administration in combination with local or systemic therapy may also lead to improved outcomes. Although anti-PD-1 Ab-based combined therapy might be effective for the treatment of advanced melanoma, the associated risk of irAEs is an important consideration. Therefore, being able to predict irAEs is of great interest to oncologists. The purpose of this study was to evaluate the value of using serum levels of sCD163 and CXCL5 to predict irAEs in patients with advanced melanoma who were administered nivolumab. To this end, we analyzed these serum levels in 46 cases of advanced melanoma treated with nivolumab. In addition, the tumor stroma was evaluated by immunohistochemistry and immunofluorescence. We measured the serum levels of sCD163 and CXCL5 on day 0 (immediately before nivolumab administration) and day 42. The serum absolute levels of sCD163 were significantly increased in patients who developed AEs (p = 0.0018). Although there was no significant difference in serum levels of CXCL5, the absolute value of CXCL5 could at least be a supportive marker for the increased absolute levels of serum sCD163. This study suggests that sCD163 and CXCL5 may serve as possible prognostic biomarkers for irAEs in patients with advanced melanoma treated with nivolumab.

AB - Antibodies against PD-1, such as nivolumab and pembrolizumab, are widely used in the treatment of various cancers including advanced melanoma. The anti- PD-1 Ab significantly prolongs survival in patients with metastatic melanoma, and its administration in combination with local or systemic therapy may also lead to improved outcomes. Although anti-PD-1 Ab-based combined therapy might be effective for the treatment of advanced melanoma, the associated risk of irAEs is an important consideration. Therefore, being able to predict irAEs is of great interest to oncologists. The purpose of this study was to evaluate the value of using serum levels of sCD163 and CXCL5 to predict irAEs in patients with advanced melanoma who were administered nivolumab. To this end, we analyzed these serum levels in 46 cases of advanced melanoma treated with nivolumab. In addition, the tumor stroma was evaluated by immunohistochemistry and immunofluorescence. We measured the serum levels of sCD163 and CXCL5 on day 0 (immediately before nivolumab administration) and day 42. The serum absolute levels of sCD163 were significantly increased in patients who developed AEs (p = 0.0018). Although there was no significant difference in serum levels of CXCL5, the absolute value of CXCL5 could at least be a supportive marker for the increased absolute levels of serum sCD163. This study suggests that sCD163 and CXCL5 may serve as possible prognostic biomarkers for irAEs in patients with advanced melanoma treated with nivolumab.

KW - CXCL5

KW - Melanoma

KW - POSTN

KW - SCD163

KW - TAMs

UR - http://www.scopus.com/inward/record.url?scp=85044223008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044223008&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.24509

DO - 10.18632/oncotarget.24509

M3 - Article

AN - SCOPUS:85044223008

VL - 9

SP - 15542

EP - 15551

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 21

ER -